About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The aim of our group is to investigate the use of medicines and evaluate its benefit/risk relationship in usual clinical practice. Our group coordinates the Catalan centre of the Spanish System of Pharmacovigilance. Research activities on pharmacology and pharmacoepidemiology are coupled with undergraduate teaching at the Autonomous University of Barcelona Medical School, training of specialists in clinical pharmacology, and continuous education of health professionals on therapeutics.
The group is a Special Group of Research recognized by AGAUR GenCat. It is a partner of “The European Consortium “EU PE&PV Network” (European Pharmacoepidemiology and Pharmacovigilance Network)” and it is part of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). It gives institutional support to the Clinical Research Ethical Committee of the University hospital Vall d’Hebron (UHVH), the Drug and Pharmacotherapeutic Committee of the UHVH, and also to the Drug and Pharmacotherapeutic Committee of the Institut Català de la Salut.
In this line of research, studies of the use of drugs in real clinical practice are mainly carried out, such as monitoring the use of outpatient hospital drugs and medicines evaluated for their special conditions of use (e.g. off-label and compassionate use).
In addition, research is being carried out into the use of medicines within a European consortium led by Utrecht University EU PE&PV, and at the request of the European Medicines Agency (e.g. use of retinoids in women of childbearing age).
IP: Immaculada Danes Carreras, Mònica Sabaté Gallego
Primarily focused on the analysis of acute and chronic postoperative pain and neuropathic pain.
IP: Francisco Javier Medel Rebollo
Analysis of the spontaneous reported adverse drug reactions at the Hospital, in order to improve knowledge of the safety profile of new commercialized drugs and to be able to estimate the incidence of their adverse drug reactions. Analysis of the drug use in the real world setting in order to improve the prevention of adverse drug reactions.
IP: Maria Antònia Agustí Escasany, Cristina Aguilera Martin
In collaboration with three hospitals of the Metropolitan Area of Barcelona the group performs two studies to identify hospital admissions due to acute renal failure and hospital-acquired acute renal failure related to rennin-angiotensin-aldosterone system and other drugs with in-hospital use. The aim is to estimate the incidence rate and the severity, to describe the clinic characteristics and clinical course, the drugs involved, other associated risk factors, the length of the hospital stay, and the economical impact.
IP: Maria Antònia Agustí Escasany
IP: Mònica Sabaté Gallego Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 49500 Reference: TARGET_EMA_TDA2024 Duration: 06/02/2025 - 14/10/2026
IP: Mònica Sabaté Gallego Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 3630 Reference: EMA/NO.20-2020-46-TDA-LOT5/2024/SABATÉ Duration: 06/02/2025 - 14/10/2026
PhD student: Elena Guillen Benitez Director/s: María Gloria Cereza García, Maria Antònia Agustí Escasany University: Year: 2024
PhD student: Carla Sans Pola, Carla Sans Pola Director/s: José Ángel Bosch Gil, Immaculada Danes Carreras, Maria Antònia Agustí Escasany University: Year: 2024
PhD student: Carolina Iglesias Lòpez Director/s: Maria Antònia Agustí Escasany, Antoni Vallano Ferraz University: Universitat Autònoma de Barcelona Year: 2023
PhD student: Lina Fernanda Camacho Arteaga, Lina Fernanda Camacho Arteaga Director/s: Mònica Sabaté Gallego, Xavier Vidal Guitart University: Universidad Autònoma de Barcelona Year: 2022
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The results show the need for continuous monitoring of patients to detect and manage possible adverse effects occurring months and years after treatment.
The creation of hybrid digital-human interaction spaces between avatars and people offers new opportunities for personalized medicine
